Resverlogix's RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23 July 2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp (TSX: RVX) has announced results it believes to be statistically significant regarding a reduction in major adverse cardiovascular events in patients with diabetes mellitus treated with RVX-208 compared to a placebo.

Resverlogix’s RVX-208 is a BET-inhibitor, which was here used to reduce cardiovascular events and additional metabolic parameters over six months in high-risk vascular patients with diabetes mellitus and low high-density lipoprotein.

Approximately 75% of study participants were given RVX-208, and a statistically significant relative risk reduction in cardiovascular events was noted in more than 65% of the patients with diabetes mellitus who were treated with the drug rather than the placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK